Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections.
Current opinion in investigational drugs (London, England : 2000) 2008 Feb 1; 9(2):210-25
Peppard W WJ, Schuenke C CD
Froedtert Hospital, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, USA. wpeppard@fmlh.edu.
Arpida Ltd, under license from Roche AG, is developing the diaminopyrimidine dihydrofolate reductase inhibitor iclaprim for the potential treatment of methicillin-resistant Staphylococcus aureus infections, including complicated skin and skin structure infections and hospital-acquired pneumonia. Phase III cSSSI clinical trials have been completed and an NDA filing process is ongoing. A phase II clinical trial for hospital-acquired pneumonia is ongoing.
Keywords: Iclaprim diaminopyrimidine dihydrofolate staphylococcal staphylococcus resistant skin structure infection skin infection pneumonia